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DeazaﬂavinBased on previous reports of certain 5-deazaﬂavin derivatives being capable of activating the tumour
suppressor p53 in cancer cells through inhibition of the p53-speciﬁc ubiquitin E3 ligase HDM2, we have
conducted an structure–activity relationship (SAR) analysis through systematic modiﬁcation of the 5-
deazaﬂavin template. This analysis shows that HDM2-inhibitory activity depends on a combination of
factors. The most active compounds (e.g., 15) contain a triﬂuoromethyl or chloro substituent at the deaza-
ﬂavin C9 position and this activity depends to a large extent on the presence of at least one additional
halogen or methyl substituent of the phenyl group at N10. Our SAR results, in combination with the
HDM2 RING domain receptor recognition model we present, form the basis for the design of drug-like
and potent activators of p53 for potential cancer therapy.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
The tumour suppressor p53 is central to the protection of mam-
malian cells against genetic damage and p53 is dysfunctional in a
large proportion of cancer cells.1 The oncogene HDM2 and p53
are linked in a negative feed-back loop in which p53 activates
HDM2, the latter acting as a p53-speciﬁc ubiquitin E3 ligase and
thus promoting degradation of p53 protein through the ubiqui-
tin–proteasome system.2 Tumours that retain wild-type p53 fre-
quently show aberrations in p53 regulation, most commonly
through overexpression of the p53 negative regulator HDM2.3 A
strategy for the reactivation of the pro-apoptotic p53 activities in
such tumours is therefore to interrupt the p53–HDM2 feed-back
loop, either by blocking the protein–protein interaction between
the p53 N-terminal domain and HDM2, or by inhibiting the E3 li-
gase activity of HDM2.4
We have previously reported on a family of 7-nitro-5-deaza-ﬂa-
vin compounds, which were discovered in a screen for inhibitors of
HDM2 E3 activity.5 This group of compounds was named the
HDM2 ligase inhibitor 98 class (HLI98; Fig. 1). A compound known
as HLI373 (Fig. 1), whose structure differs signiﬁcantly from activeHLI98 compounds, has also been reported to inhibit the E3 ubiqui-
tin ligase activity of HDM2 and thereby selectively to kill cancer
cells in a p53-dependent manner.6 Whereas 7-nitro-5-deazaﬂavins
inhibit both HDM2-mediated p53 ubiquitination and auto-ubiqui-
tination, other reported compounds that target the ubiquitin E3 li-
gase activity of HDM2 apparently are selective for p53
ubiquitination.7
Using surface plasmon resonance spectroscopy we found that
active, but not inactive 5-deazaﬂavin analogues, bound to the
HDM2 RING domain. In cellular assays, active 5-deazaﬂavin com-
pounds inhibited p53 ubiquitination, stabilised p53, and induced
the expression of p53 targets.9
The ﬂavin and 5-deazaﬂavin (also known as 5-deaza-isoalloxa-
zine or pyrimido[4,5-b]quinoline-2,4(3H,10H)-dione (Fig. 1)) sub-
structures are found in a number of naturally occurring redox
cofactors.10,11 Various synthetic 5-deazaﬂavin derivatives have
been reported to possess antibacterial, antiparasitic, and antican-
cer pharmacological activities, although the molecular targets for
these activities remain unknown in most cases.12,13
Because of the high reduction potential of nitro-5-deazaﬂavins,
they easily undergo biological one-electron reduction to generate
nitro anion radicals, which, when present in ﬂat heteroaromatic
systems that can interact with DNA,14 are known to induce cyto-
toxicity through DNA damage.15–17 It has been shown that certain
nitro-5-deazaﬂavins have antitumour activities18 and that 6- and
8-nitro derivatives (containing long-chain alkyl groups at N10 in-
stead of the phenyl group present in HLI98 compounds) generate
Figure 1. The chemical structures of ﬂavin and 5-deazaﬂavin (numbering system
indicated in blue), as well as derivatives of 5-deazaﬂavin known as HDM2 ligase
inhibitors (HLI).5,6,8
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against hypoxic cells.19 Furthermore, direct interaction between a
5-deazaﬂavin–oligonucleotide conjugate and DNA has been
demonstrated.20,21Table 1
Inhibition of in vitro ubiquitination of p53 by HDM2 by substituted 10-aryl (I) and 10-alk
Compd
R1 R2 R3 R4 R5 R
5 (I) H H H NO2 F H
6 (I) H NO2 H H H H
7 (I) H H H NO2 H H
8 (I) H H H CF3 H H
9 (I) H H CF3 H F H
10 (I) H H H CF3 F H
11 (I) CF3 H H H H H
12 (I) H CF3 H H H H
13 (I) H H CF3 H H H
14 (I) H H H CF3 H H
15 (I) H H H CF3 H C
16 (I) H H H CF3 H C
17 (I) H H H CF3 H F
18 (I) H H H CF3 H H
19 (I) H H H CF3 H M
20 (I) H H H CF3 H H
21 (II) H H H CF3 — —
22 (I) H H H Cl H H
23 (I) H Cl H H F H
24 (I) Cl H H H H H
25 (I) H H H Cl H H
26 (I) H H H Cl H C
27 (I) H H H Cl H F
28 (I) H H Me H H H
29 (I) H H H Br H H
30 (I) H H H Br H H
a For explanation of prescreen refer to text; for summary of inactive compounds refe
b IC50 values correspond to those reported previously9 for compounds 8, 10, 14–20, 25
146, 32, 39, and 159, respectively, in Ref. 9.With regards to the HLI98 class of compounds as leads for phar-
macological p53 reactivation, we were interested in abolishing the
possibility of their promiscuous cytotoxic activity through biore-
ductive activation and DNA damage. Preliminary SAR studies indi-
cated that the cellular activity of 10-aryl-5-deazaﬂavins was in fact
not due to the C7-nitro function, since both cell-inactive 7-nitro
derivatives and cell-active analogues devoid of the 7-nitro group
were observed.8 Here we report on the synthesis and structure–
activity relationships (SARs) with respect to HDM2 E3 ligase inhi-
bition and cellular activity of an extensive set of 5-deazaﬂavin
derivatives.
2. Chemistry
The 5-deazaﬂavins 5–96 (Table 1 & Table S1) were prepared as
shown in Scheme 1. 6-Chlorouracil 2, prepared by hydrolysis of
2,4,6-trichloropyrimidine 1,22 was fused with the appropriate ani-
lines or other primary amines to afford the 6-anilinouracils 3a and
6-(ar)alkyluracils 3b in moderate to high yield.23 These were then
submitted to cyclocondensation with 2-halobenzaldehydes 4.8,24,25
The latter were chosen depending on commercial availability. The
6-chlorodeazaﬂavins could be prepared unambiguously using 2-
chloro-6-ﬂuorobenzaldehyde, due to the enhanced reactivity of
the ortho-ﬂuoro compared to the ortho-chloro group in the cyclo-
condensation reaction.yldeazaﬂavins (II)a
Prescreen IC50 (lM)
6 R7 R8 R9
H H — Active >100
Cl H — Active >75
Cl H — Active >50
H H — Active 17.5b
H H — Active >100
H H — Active 19.6b
Cl H — Active >100
Cl H — Active >100
Cl H — Active >100
Cl H — Active 11.9b
l H H — Active 1.5b
l Cl H — Active 10.7b
H H — Active 12.3b
F H — Active 13.1b
e H H — Active 8.4b
Me H — Active 32b
— H Bn Active >100
H H — Active >100
H H — Active >100
Cl H — Active >100
Cl H — Active 15.0b
l H H — Active >100
H H — Active >100
Cl H — Active >100b
H H — Active >100
Cl H — Active 49.5b
r to Table S1.
, 28, and 30; corresponding to MPD compounds 19, 20, 37, 131, 162, 134, 137, 140,
Figure 2. Example of p53 ubiquitination assay for selected compounds (refer
Table 1). Western blots with anti-p53 antibody of SDS–PAGE separation of reaction
mixtures after incubation of immobilised HDM2 with test compounds or diluent
only (C) and p53, ubiquitin, and ubiquitin ligases (-E2 indicates reactions omitting
E2 ligase). Prescreen at 50–250 lM for compounds with different activity levels (a)
and titration of compound 15 (b). The positions of p53, mono-ubiquitinated (Ub-
53), and poly-ubiquitinated p53 (Ubn-p53) are indicated.
Scheme 1. Synthesis of 5-deazaﬂavin derivatives 5–96. For deﬁnition of substit-
uents R1–9 refer to Table 1.
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starting materials were available, 2-tosylbenzaldehydes (4,
X = OTs) were prepared and used successfully in the deazaﬂavin
cyclocondensation reaction. Other benzaldehydes were prepared
by literature procedures. Thus 2-ﬂuoro-6-nitrobenzaldehyde was
prepared from 2-ﬂuoro-6-nitrotoluene by the nitrone method,26
whereas 2-chloro-4-nitrobenzaldehyde27 was prepared from
methyl 2-chlorobenzoate by (iBu2AlH)2 reduction.28 3-Formyl-2-
hydroxybenzonitrile was obtained by Reimer-Tiemann ortho-
formylation of 2-hydroxybenzonitrile.29
3. Results and discussion
Test compounds were assayed for inhibition of p53 ubiquitina-
tion9,30 by incubation with GST-tagged HDM2, immobilised on glu-
tathione-Sepharose, p53, ubiquitin, as well as E1 and E2 (UbcH5B)
ligases, in an assay buffer containing ATP. The reaction products
were then resolved by SDS–PAGE and p53 ubiquitination was
quantitated by Western blotting using an anti-p53 antibody
(Fig. 2).31 Test compounds that were active as inhibitors at concen-
trations below 100 lM in this assay (labelled ‘prescreen’ in Table 1)
were then subjected to determination of half-maximal inhibition
concentration (IC50) of p53 ubiquitination using essentially the
same assay methodology, except that a ﬂuorescently labelled form
of ubiquitin was used. After completion of the ubiquitination reac-
tion, excess ﬂuorescent ubiquitin was removed from the immobi-lised p53–HDM2 complex by centrifugation, and incorporation of
ubiquitin was measured by ﬂuorescence spectroscopy.
Based on the original HLI98 7-nitro-5-deazaﬂavins, we exam-
ined the role of the nitro substituent in the benzene ring of the tri-
cyclic deazaﬂavin system (Table 1 & Table S1). As expected,5,8 we
conﬁrmed the activity of the 7-nitro derivative containing a para-
chloro-substituted 10-phenyl group (6). However, we also found
that introduction of a nitro group at C9 resulted in moderately ac-
tive compounds in the context of either a 10-para-chlorophenyl (7)
or 10-ortho-ﬂuorophenyl group (5). Substituents on the 10-phenyl
group appeared to be important, since the 7-nitro derivative con-
taining an unsubstituted 10-phenyl group (32; refer Table S1 for
summary of inactive compounds) was inactive.
As mentioned previously, we were interested in removing the
nitro group altogether and therefore turned our attention to
replacing this group with alternative substituents. The triﬂuoro-
methyl group has similar steric and electronic properties to the ni-
tro group and we examined a number of 5-deazaﬂavin derivatives
incorporating this function. We observed that in the absence of
substituents on the 10-phenyl group, introduction of a triﬂuoro-
methyl group in the benzene ring of the 5-deazaﬂavin tricyclic sys-
tem only afforded an active compound in the case of the 9-
triﬂuoromethyl derivative 8.
In the case of analogues with the 6-, 7-, 8-, or 9-triﬂuoro-methyl
groups in combination with either the 10-ortho-ﬂuorophenyl or
10-para-chlorophenyl substitutions, similar results were observed
insofar as only the 9-triﬂuoromethyl derivatives 8 and 10 showed
signiﬁcant biological activity, whereas the compounds with the tri-
ﬂuoromethyl group at other positions were less active (9, 11–13).
The 9-triﬂuoromethyl compounds 8 and 10 were observed to have
signiﬁcantly enhanced potency compared to the corresponding 9-
nitro compounds 5 and 7. Further elaboration of the halogen sub-
stituents on the 10-phenyl group in the context of the 9-triﬂuoro-
methyl-5-deazaﬂavin system revealed that chloro and ﬂuoro
groups were in fact also tolerated in the meta- and para-positions
(14–18), but not in the ortho-position in the case of the larger
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meta-chloro derivative 15.
A similar situation was revealed when the 10-phenyl halogen
substituents in 9-triﬂuoromethyl-5-deazaﬂavins were replaced
with methyl groups. Of the three 10-toluyl derivatives assayed,
the meta-isomer 19 was most active, followed by the less potent
para-isomer 20. As in the nitro series, modiﬁcation of the active
9-triﬂuoro-methyl-10-aryl-5-deazaﬂavin core by alkylation at N3
(62 and 63; Table S1) abolished activity, and the only replacement
of the 10-aryl group that was tolerated was with a benzyl group
(21).
We next examined the effect of groups other than the strongly
electron-withdrawing nitro and triﬂuoromethyl functions on the
biological activity of 5-deazaﬂavin compounds. The weakly elec-
tron-withdrawing chloro substituent in the contexts of an unsub-
stituted, ortho-ﬂuoro- or para-chloro-substituted 10-phenyl
group resulted in poorly active (22–24) or inactive derivatives,
with the exception of the combination of chloro substituents at
both C9 and at the para-position of the 10-phenyl group, which
afforded a compound (25) with reasonable activity. This situation
is similar to the SARs in the 9-triﬂuoro-methyl series; however,
here alternative halogen substitutions in the 10-phenyl group were
less well tolerated (26 and 27).
Replacement of the electron-withdrawing nitro, triﬂuoro-
methyl, or chloro substituents in the benzene ring of the 5-deaza-
ﬂavin ring system with the electron-releasing and sterically
undemanding methyl group resulted in inactive compounds when
the 10-phenyl group was unsubstituted. Unlike in the case of the 9-
triﬂuoromethyl series, in the otherwise active context of the para-
chloro- or ortho-ﬂuoro-substituted 10-phenyl group, this resulted
in a clear loss or decline in biological activity in all cases, with only
compound 28 retaining marginal activity.
In the case of the more strongly electron-releasing hydroxyl
group at positions C9 of the deazaﬂavin system, no biological activ-
ity was obtained, regardless of 10-phenyl substitution. However, 9-
bromo (29 and 30) and 9-ﬂuoro derivatives were also compara-
tively inactive, and the same was true for both derivatives with
the strongly electron-withdrawing cyano group at C9 (95 and 96;
Table S1).
Overall these results suggest that the SARs for inhibition of
HDM2 E3 ubiquitin ligase activity in substituted 5-deazaﬂavin
derivatives depend on a combination of factors. The most active
compounds contain a triﬂuoromethyl or chloro substituent at C9
and this activity depends to a large extent on the presence of at
least one additional halogen or methyl substituent of the phenyl
group at N10. Although we have not yet tackled modiﬁcation of
the heterocyclic rings in the 5-deazaﬂavin system extensively,
SARs in that region appear to be quite restrictive and neither
replacement of the (substituted) 10-phenyl nor the N3-H appear
to be tolerated. Selectivity of the 5-deazaﬂavins described here
for the HDM2 E3 ubiquitin ligase has been demonstrated previ-
ously9 using similar assay systems for inhibition of auto-ubiquiti-
nation of either HDM2 or the related RING E3 ubiquitin ligase
CBL.32
Some of the compound structures described here coincide with
those reported earlier by Wilson et al.8 and in general there is
agreement between the in vitro activity described here and the
activity of the relevant compounds in cells, as measured by Wilson
et al.8 However, two 6-chloro-5-deazaﬂavin derivatives described
by Wilson et al. (24 and 69, corresponding to compounds 14 and
16, respectively, in Wilson et al.8) were found to activate p53 in
cells, while our data indicate that these compounds cannot directly
inhibit HDM2. These results suggest that these compounds induce
p53 through an indirect mechanism in cells, and that the cell activ-
ity is an off-target effect. In the in vitro assays described here, we
show that the 9-triﬂuoromethyl-5-deazaﬂavins are the most activecompounds. Only two of these were reported by Wilson et al.8 (10
and 18, corresponding to compounds 27 and 28, respectively, in
Wilson et al.8), and both were found to be inactive in cells. To re-
solve this apparent paradox, we compared our compound analyses
with those reported by Wilson et al.8 We found that spectroscopic
data matched well in some cases but detected discrepancies for
those compounds where the pharmacological data is at variance
(i.e. 10 and 18, corresponding to compounds 27 and 28, respec-
tively, in Wilson et al.8). In these cases there is poor correlation be-
tween the 13C NMR spectra and in each case the 1H NMR
description in Wilson et al.8 lacks the characteristic singlet peak
for the C5-H resonance in the d 9.0–9.3 region, which we observe
in the spectra of all our compounds. During subsequent biological
testing of the compounds synthesised here, we noted a cumulative
loss of activity for several of the active compounds, suggesting that
they may show instability. We therefore believe that this instabil-
ity of these compounds may account for the apparent discrepan-
cies in biological activity and spectroscopic data.
Both 5-deazaﬂavins (X = CH, Fig. 1) and ﬂavins (X = N) contain a
redox system and undergo facile hydride transfer reduction and
the reduced 1,5-dihydro species are oxidised back readily.11,33 In
the case of 5-deazaﬂavins, which contain an electrophilic CH func-
tion at C5, nucleophilic attack at that position is comparatively fac-
ile. Electron withdrawing substituents such as nitro,
triﬂuoromethyl, etc. in the tricyclic system enhance the reactivity
of the redox system34 and it would therefore be important to de-
velop potent analogues that have neutral or electron-donating sub-
stituents in the benzo ring, since these should be more stable.
Apart from extending the SARs of the 5-deazaﬂavins through syn-
thesis and testing of more analogues, the most important aspect
would be to modulate the electrophilic reactivity of the system.
This inherent property is undesirable because reactivity, especially
as far as interference with physiological redox systems is con-
cerned, might lead to poor bioavailability and potentially toxicity.
It should be noted, however, that even ﬂavins, which are more
reactive than 5-deazaﬂavins, appear to have drug-like properties
potential, based on the fact that certain ﬂavin derivatives with
antimalarial activity and close structural similarity to the 5-deazaf-
lavins of the current report, have been shown to possess in vivo
activity by both the parenteral and oral administration routes in
a malaria mouse model.13,35
Despite the availability of structural information on the HDM2
RING domain,36–39 its E3 ligase catalytic mechanism remains un-
clear since neither the nucleotide-binding site nor the active site
have been delineated. The structural basis of the inhibition of the
HDM2 E3 ligase activity by our compounds thus also remains
uncertain. It has been shown that the extreme C-terminal tripep-
tide of HDM2 is critical for the HDM2 E3 ligase activity40,41 and a
structural solution of an HDM2–HDMX RING domain heterodi-
mer38 shows that this tripeptide binds a groove of the partner pro-
tein, thus forming a composite binding site for the E2-ubiquitin
complex (Fig. 3a & b). Since this interaction is apparently required
for HDM2 E3 ligase activity both in trans and in cis,40 it is possible
that nonselective inhibitors, i.e. compounds such as our 5-deazaf-
lavins that do not distinguish between inhibition of HDM2 auto-
ubiquitination and ubiquitination of p53,9 target this E2-binding
site.
We therefore extracted the coordinates of the HDM2 RING
domain38 and docked bioactive 5-deazaﬂavins to this receptor by
deﬁning the entire domain as the receptor site. We found that all
plausible and highly scoring poses put the ligands exactly where
the tripeptide tail in the above complex structure is (Fig. 3c). In fact
it can be observed that the 5-deazaﬂavins appear to mimic the ter-
minal residues of the peptide, with the substituted fused phenyl
ring of the 5-deazaﬂavin system occupying the position of the Ile
residue, the pyrimidinedione ring in the position of the Ala residue,
Figure 3. HDM2–HDMX RING domain heterodimer complex (constructed from
PDB entry 2VJF). (a) Secondary structure cartoon with HDM2 in green and HDMX in
cyan. The two zinc ions in each RING domain are shown as spheres with the
coordinating residue side chains as sticks. A composite of one face of HDM2,
together with the C-terminus of HDMX (key residues shown with side chains and
labelled), forms the likely interaction site with the E2 ubiquitin conjugating
enzyme. (b) Interaction of the C-terminus of HDMX (cyan) with HDM2 (green CPK
surface). (c) Predominant docked poses of compounds HLI98C (magenta) and 15
(yellow).
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main determinant of activity, i.e. a 9-triﬂuoromethyl group, may
be due to favourable interactions of that group with a pocket delin-
eated by HDM2 residues Leu430 and Leu458. Substitution at C9 of
the 5-deazaﬂavin system also imposes rotational limitations on
the 10-aryl group, thus locking this group into conformations
which positions its halogen substituents, which are important for
activity, for interactions with either His457 or Leu430–Pro431. While
these ﬁnding are suggestive, it remains to be shown experimen-
tally that HDM2-inhibitory 5-deazaﬂavins compete directly with
the C-terminal peptide.
4. Conclusion
Following our recent elucidation of the fact that bioactive 5-
deazaﬂavins stabilize and activate p53 by binding directly to the
HDM2 RING domain,9 here we have presented a comprehensive
SAR analysis of 5-deazaﬂavin as inhibitors of p53 ubiquitination
by the p53-speciﬁc ubiquitin E3 ligase HDM2. Together with the
structural model of the mode of interaction of 5-deazaﬂavins with
HDM2, it should now be possible to design and develop drug-like
and potent inhibitors of HDM2 E3 ligase activity for potential ther-
apeutic application in oncology.
5. Experimental section
5.1. General
Silica gel (Merck Kieselgel 60, 230–400) ﬂash column chroma-
tography was carried out as described42 or using Biotage Argonaut
Flash Master II and Biotage Flash Master Personal instruments.Melting points were recorded using Gallenkamp and Bibby Stuart
Scientiﬁc (SMP3) apparatus and are uncorrected. NMR spectra
were recorded on a Bruker-AV 400 instrument at 400.1 MHz (1H)
or 75 MHz (13C) with compound solutions in DMSO-d6 (unless
otherwise indicated). Chemical shifts (d) are reported in ppm with
reference to the chemical shift of residual solvent or the internal
standard SiMe4. Mass spectra (TOF-ES) were recorded using a
Waters 2795 Separation Module and Micromass LCT platform.
Infrared spectra were recorded using Avatar 360 Nicolet FT-IR
and Nicolet IR200 FT-IR spectrophotometers. AWaters 2525 Binary
Gradient Module was used for analytical RP-HPLC with a Waters
2487 Dual Wavelength Absorbance UV Detector. Analytical
RP-HPLC was used to conﬁrm purity for all compounds by chro-
matogram integration at 254 nm, using two systems. System A:
Phenomenex Onyx monolithic reversed phase C18 column
(100  3.0 mm) with a ﬂow rate of 3 mL/min and using isocratic
elution with 7:3 H2O–MeCN. System B: Phenomenex Kromasil
reversed phase C18 column (250  4.6 mm) with a ﬂow rate of
1 mL/min and using isocratic elution with 1:1 H2O–MeOH. Biolog-
ical assays were carried out as described.95.2. General method for the preparation of 6-anilinouracils (3a)
To 6-chlorouracil (2, 1 equiv) was added the appropriate aniline
(6 equiv) and the mixture was heated at 180–200 C for 1.5–3 h. It
was then cooled and the residue was triturated with Et2O. Precip-
itated product was ﬁltered and washed on a sinter with Et2O and
H2O. After drying, the crude product was crystallised from EtOH.
In this manner pure 6-anilinouracils 3a were obtained, whose
analytical details were in accord with the literature. E.g. 6-[(3-
methylphenyl)amino]-1,2,3,4-tetrahydropyrimidine-2,4-dione
(3a, R5,7 = H, R6 = Me) in 71% yield as an off-white solid with mp
303–304 C (lit.43 302–303 C); IR (KBr): 3211 (NH), 3053 (NH),
1734 (C@O), 1625 (C@C) cm1; 1H NMR: d 2.30 (3H, s, Me), 4.68
(1H, s, C5-H), 6.95–7.02 (3H, m, Ph-H), 7.26 (1H, t, J = 7.5 Hz, Ph
5-H), 8.16 (1H, s, NH), 10.10 (1H, s, N1-H), 10.43 (1H, s, N3-H);
13C NMR: d 17.78 (CH3), 75.21 (CH), 126.66 (CH), 127.07 (CH),
127.32 (CH), 131.45 (CH), 134.21 (Cq), 136.12 (Cq), 151.29 (Cq),
153.54 (Cq), 164.70 (Cq); HRMS (ESI+): calcd for C11H12N3O2
[M+H]+ 218.0930, found 218.0923.5.3. General method for the preparation of 2-tosylbenzalde-
hydes (4, X = OTs)
A mixture of the appropriate salicylaldehyde (1 equiv) and Na2-
CO3 (4 equiv) in Me2CO (5 mL/mmol salicylaldehyde) was stirred
for 30 min under N2, when tosyl chloride (2 equiv) in Me2CO
(2 mL/mmol) was added. The solution was heated under reﬂux
for 5 h, cooled, and concentrated under reduced pressure. The res-
idue was puriﬁed by ﬂash chromatography (2:1 hexane–Et2O) to
afford the product.5.4. 2-Formyl-5-methylphenyl 4-methylbenzene-1-sulfonate (4,
R1,2,4 = H, R3 = Me, X = OTs)
Prepared using general method 5.3 from 2-hydroxy-4-methyl-
benzaldehyde (0.50 g, 3.7 mmol). White solid (0.63 g, 59%). Mp
93–94 C; 1H NMR: d 2.36 (3H, s, Me), 2.42 (3H, s, Me), 7.06 (1H,
s, C3-H), 7.33 (1H, d, J = 7.8 Hz, C5-H), 7.48 (2H, d, J = 8.2 Hz, Ph
3-H), 7.70 (1H, d, J = 7.8 Hz, C6-H), 7.76 (2H, d, J = 8.2 Hz, Ph 2-
H), 9.83 (1H, s, CHO); 13C NMR: d 21.65 (CH3), 21.66 (CH3),
124.44 (CH), 126.96 (Cq), 128.86 (CH), 128.96 (CH), 129.31 (CH),
130.85 (CH), 130.90 (Cq), 146.95 (Cq), 147.74 (Cq), 150.51 (Cq),
187.45 (CH).
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R1–3 = H, R4 = Br, X = OTs)
Prepared using general method 5.3 from 3-bromo-2-hydroxy-
benzaldehyde (0.57 g, 2.8 mmol). White solid (0.82 g, 82%). Mp
79–91 C; 1H NMR: d 2.46 (3H, s, Me), 7.44–7.58 (3H, m), 7.77–
7.88 (3H, m), 8.05 (1H, d, J = 7.3 Hz, C4-H), 9.86 (1H, s, CHO); 13C
NMR: d 21.74 (CH3), 118.58 (Cq), 128.40 (CH), 129.17 (CH),
129.94 (CH), 131.02 (CH), 131.28 (Cq), 132.40 (Cq), 139.98 (CH),
147.44 (Cq), 147.65 (Cq), 187.53 (CH).
5.6. 2-Cyano-6-formylphenyl 4-methylbenzene-1-sulfonate (4,
R1–3 = H, R4 = CN, X = OTs)
Prepared using general method 5.3 from 3-formyl-2-hydrox-
ybenzonitrile (0.34 g, 1.7 mmol).29 White solid (0.48 g, 94%). Mp
84–86 C; 1H NMR: d 2.46 (3H, s, Me), 7.55 (2H, d, J = 8.5 Hz, Ph
3-H), 7.75 (1H, t, J = 7.6 Hz, C5-H), 7.82 (2H, d, J = 8.5 Hz, Ph 2-H),
8.15 (1H, dd, J = 1.8, 7.6 Hz, C6-H), 8.28 (1H, dd, J = 1.8, 7.6 Hz,
C4-H), 9.84 (1H, s, CHO); 13C NMR: d 21.76 (CH3), 109.73 (Cq),
114.46 (Cq), 129.27 (CH), 129.55 (CH), 129.95 (Cq), 131.22 (Cq),
131.25 (CH), 133.78 (CH), 140.01 (CH), 148.06 (Cq), 150.68 (Cq),
186.55 (CH).
5.7. General method for the preparation of 10-aryl-5-deaza-
ﬂavins using 2-halobenzaldehydes or 2-tosylbenzaldehydes
A mixture of a 6-(arylamino)pyrimidine-2,4(1H,3H)-dione 3a
(1 equiv) and a 2-halo- or 2-tosyl-benzaldehyde 4 (X = F, Cl, or
OTs; 1.2 equiv) in DMF (10 mL/mmol 3a) was heated under reﬂux
for 4 h. After cooling, the solution was evaporated under reduced
pressure and the residue was puriﬁed by ﬂash chromatography
(5:95 MeOH–CH2Cl2) to afford the product.
5.8. 10-(2-Fluorophenyl)-9-nitro-2H,3H,4H,10H-pyrimido[4, 5-
b]quinoline-2,4-dione (5)
Prepared using general method 5.7 from 3a (R5 = F, R6,7 = H;
62 mg, 0.28 mmol) and 4 (R1–3 = H, R4 = NO2, X = OTs; 108 mg,
0.34 mmol).44,45 Yellow solid (23.0 mg, 23%). Mp: 305–307 C; IR
(KBr): 3.425 (NH), 1.712 (C@O), 1.679 (C@O), 1.619 (C@C), 1.487
(NO2), 1.328 (NO2) cm1; 1H NMR: d 7.25 (1H, t, J = 7.5 Hz, Ph 5-
H), 7.35–7.44 (2H, m, Ph-H), 7.56–7.74 (2H, m, C7-H & Ph-H),
8.17 (1H, d, J = 7.3 Hz, C8-H), 8.50 (1H, d, J = 7.3 Hz, C6-H), 9.19
(1H, s, C5-H), 11.36 (1H, s, N3-H); 13C NMR: d 116.72 (CH, d,
J = 19.6 Hz), 117.13 (Cq), 124.05 (Cq), 125.11 (CH), 125.21 (Cq),
125.34 (Cq), 125.36 (CH), 130.03 (CH), 132.60 (CH), 133.12 (CH,
d, J = 8.0 Hz), 136.17 (CH), 140.85 (Cq), 142.95 (CH), 156.53 (Cq),
158.52 (Cq, d, J = 252.4 Hz), 159.51 (Cq), 161.71 (Cq); anal. RP-
HPLC: tR 1.10 min (100%, A), 3.98 min (97.6%, B); HRMS (ESI+):
calcd for C17H10FN4O4 [M+H]+ 353.0681, found 353.0676.
5.9. 10-(4-Chlorophenyl)-9-nitro-2H,3H,4H,10H-pyrimido[4, 5-
b]quinoline-2,4-dione (7)
Prepared using general method 5.7 from 3a (R5,6 = H, R7 = Cl;
64 mg, 0.27 mmol) and 4 (R1–3 = H, R4 = NO2, X = OTs; 104 mg,
0.32 mmol).44,45 Yellow solid (23.8 mg, 24%). Mp 336–338 C; IR
(KBr): 3.422 (NH), 1.706 (C@O), 1.672 (C@O), 1.620 (C@C), 1.427
(NO2), 1,352 (NO2) cm1; 1H NMR: d 7.41 (2H, d, J = 8.6 Hz, Ph 2-
H), 7.55 (2H, d, J = 8.6 Hz, Ph 3-H), 7.64 (1H, t, J = 7.8 Hz, C7-H),
8.13 (1H, d, J = 7.8 Hz, C8-H), 8.48 (1H, d, J = 7.8 Hz, C6-H), 9.17
(1H, s, C5-H), 11.30 (1H, s, N3-H); 13C NMR: d 117.45 (Cq),
123.98 (Cq), 124.87 (CH), 129.21 (CH), 131.40 (CH), 132.03 (CH),
132.52 (Cq), 134.63 (Cq), 135.89 (CH), 136.24 (Cq), 141.09 (Cq),
142.62 (CH), 156.53 (Cq), 160.37 (Cq), 161.86 (Cq); anal. RP-HPLC:tR 1.63 min (98.4%, A), 4.75 min (100%, B); HRMS (ESI+): calcd for
C17H10ClN4O4 [M+H]+ 369.0391, found 369.0419.
5.10. 10-Phenyl-9-(triﬂuoromethyl)-2H,3H,4H,10H-pyrimido
[4,5-b]quinoline-2,4-dione (8)
Prepared using general method 5.7 from 3a (R5–7 = H; 58 mg,
0.28 mmol)46 and 4 (R1–3 = H, R4 = CF3, X = F; 65 mg, 0.34 mmol).
Yellow solid (23.2 mg, 23%). Mp 312–314 C; IR (KBr): 3.424
(NH), 1.716 (C@O), 1.659 (C@O), 1.618 (C@C) cm1; 1H NMR: d
7.30–7.36 (2H, m, Ph 2-H), 7.45–7.51 (3H, m, Ph-H), 7.66 (1H, t,
J = 7.7 Hz, C7-H), 8.18 (1H, dd, 4J = 1.4 Hz, 3J = 7.7 Hz, C8-H), 8.48
(1H, dd, 4J = 1.4 Hz, 3J = 7.7 Hz, C6-H), 9.11 (1H, s, C5-H), 11.23
(1H, s, N3-H); 13C NMR: d 116.79 (Cq), 120.91 (CH), 124.26 (Cq),
124.94 (CH), 128.44 (CH), 129.58 (CH), 129.90 (CH), 131.20 (CH),
136.79 (Cq), 139.46 (Cq), 139.67 (Cq), 143.32(CH), 156.80 (Cq),
161.18 (Cq), 162.07 (Cq); anal. RP-HPLC: tR 2.12 min (100%, A),
5.20 min (100%, B); HRMS (ESI+): calcd for C18H11F3N3O2 [M+H]+
358.0803, found 358.0765.
5.11. 10-(2-Fluorophenyl)-8-(triﬂuoromethyl)-2H,3H,4H, 10H-
pyrimido[4,5-b]quinoline-2,4-dione (9)
Prepared using general method 5.7 from 3a (R5 = F, R6,7 = H;
59 mg, 0.27 mmol)8 and 4 (R1,2,4 = H, R3 = CF3, X = F; 61 mg,
0.32 mmol). Yellow solid (39.1 mg, 39%). Mp 315–318 C; IR
(KBr): 3.423 (NH), 1.708 (C@O), 1.672 (C@O), 1.622 (C@C) cm1;
1H NMR: d 6.90 (1H, s, C9-H), 7.56 (1H, t, J = 7.6 Hz, Ph 5-H),
7.62–7.69 (2H, m, Ph-H), 7.73–7.80(1H, m, Ph-H), 7.89 (1H, d,
J = 8.4 Hz, C7-H), 8.51 (1H, d, J = 8.4 Hz, C6-H), 9.23 (1H, s, C5-H),
11.34 (1H, s, N3-H); 13C NMR: d 112.97 (CH, d, J = 4.77 Hz),
117.88 (CH, d, J = 18.40 Hz), 118.28 (Cq), 121.10 (CH, d,
J = 3.62 Hz), 123.86 (Cq), 124.29 (Cq, d, J = 13.29 Hz), 126.81 (CH,
d, J = 3.52 Hz), 130.94 (CH), 133.06 (CH, d, J = 8.09 Hz), 133.93
(CH), 134.27 (Cq), 141.12 (Cq), 142.34 (CH), 156.63 (Cq), 157.58
(Cq, d, J = 251.92 Hz), 159.17 (Cq), 161.77 (Cq); anal. RP-HPLC: tR
3.59 min (97.3%, A), 6.42 min (100%, B); HRMS (ESI+): calcd for C18-
H10F4N3O2 [M+H]+ 376.0709, found 376.0705.
5.12. 10-(2-Fluorophenyl)-9-(triﬂuoromethyl)-2H,3H,4H, 10H-
pyrimido[4,5-b]quinoline-2,4-dione (10)
Prepared using general method 5.7 from 3a (R5 = F, R6,7 = H;
59 mg, 0.27 mmol)8 and 4 (R1–3 = H, R4 = CF3, X = F; 62 mg,
0.32 mmol). Yellow solid (65.7 mg, 66%). Mp: 292–293 C (lit.8
>360 C); IR (KBr): 3.418 (NH), 1.703 (C@O), 1.679 (C@O), 1,631
(C@C) cm1; 1H NMR: d 7.25–7.31(2H, m, Ph-H), 7.42 (1H, t,
J = 9.7 Hz, Ph 5-H), 7.55–7.63 (1H, m, Ph-H), 7.69 (1H, t,
J = 7.9 Hz, C7-H), 8.23 (1H, dd, 4J = 1.3 Hz, 3J = 7.9 Hz, C8-H), 8.52
(1H, dd, 4J = 1.3 Hz, 3J = 7.9 Hz, C6-H), 9.15 (1H, s, C5-H), 11.32
(1H, s, N3-H); 13C NMR: d 115.80 (CH, d, J = 20.1 Hz), 116.05
(CH), 123.89 (Cq), 124.64 (Cq), 126.75 (CH, d, J = 3.6 Hz), 129.70
(CH), 130.95 (CH), 131.14 (Cq), 131.99 (CH, d, J = 7.64 Hz), 135.36
(Cq), 136.91 (Cq), 139.57 (Cq), 143.28 (CH), 156.26 (Cq), 158.77
(Cq, d, J = 251.8 Hz), 159.99 (Cq), 161.45 (Cq); anal. RP-HPLC: tR
2.52 min (98.0%, A), 5.62 min (97.5%, B); HRMS (ESI+): calcd for C18-
H10F4N3O2 [M+H]+ 376.0709, found 376.0729.
5.13. 10-(4-Chlorophenyl)-6-(triﬂuoromethyl)-2H,3H,4H, 10H-
pyrimido[4,5-b]quinoline-2,4-dione (11)
Prepared using general method 5.7 from 3a (R5,6 = H, R7 = Cl;
61 mg, 0.26 mmol)25 and 4 (R1 = CF3, R2–4 = H, X = F; 60 mg,
0.31 mmol). Yellow solid (11.1 mg, 11%). Mp 304–306 C; IR
(KBr): 3.410 (NH), 1.716 (C = O), 1.670 (C@O), 1624 (C@C) cm1;
1H NMR: d 7.16 (1H, d, J = 8.0 Hz, C9-H), 7.52 (2H, d, J = 8.8 Hz,
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H), 7.97 (1H, d, J = 8.0 Hz, C7-H), 8.86 (1H, s, C5-H), 11.33 (1H, s,
N3-H); 13C NMR: d 116.89 (Cq), 118.04 (Cq), 122.94 (CH), 123.27
(CH), 127.48 (Cq), 130.86 (CH), 130.99 (CH), 134.66 (CH), 134.83
(Cq), 135.64 (CH), 136.70 (Cq), 143.28 (Cq), 156.53 (Cq), 158.80
(Cq), 161.88 (Cq); anal. RP-HPLC: tR 3.98 min (100%, A), 7.47 min
(96.2%, B); HRMS (ESI+): calcd for C18H10ClF3N3O2 [M+H]+
392.0414, found 392.0439.
5.14. 10-(4-Chlorophenyl)-8-(triﬂuoromethyl)-2H,3H,4H, 10H-
pyrimido[4,5-b]quinoline-2,4-dione (13)
Prepared using general method 5.7 from 3a (R5,6 = H, R7 = Cl;
84 mg, 0.35 mmol)25 and 4 (R1,2,4 = H, R3 = CF3, X = F; 81 mg,
0.42 mmol). Yellow solid (70.8 mg, 51%). Mp 348–349 C (dec); IR
(KBr): 3.430 (NH), 1.716 (C@O), 1.683 (C@O), 1.650 (C@C) cm1;
1H NMR: d 6.89 (1H, s, C9-H), 7.54 (2H, d, J = 8.7 Hz, Ph 2-H),
7.81(2H, d, J = 8.7 Hz, Ph 3-H), 7.86 (1H, d, J = 8.2 Hz, C7-H), 8.49
(1H, d, J = 8.2 Hz, C6-H), 9.22 (1H, s, C5-H), 11.28 (1H, s, N3-H);
13C NMR: d 118.40 (CH), 120.69 (CH), 120.72 (CH), 122.36 (Cq),
123.96 (Cq), 130.94 (CH), 131.06 (CH), 133.59 (CH), 134.92 (Cq),
136.31 (Cq), 141.79 (Cq), 141.94 (CH), 156.67 (Cq), 159.58 (Cq),
161.97 (Cq); anal. RP-HPLC: tR 6.18 min (100%, A), 8.60 min
(97.4%, B). HRMS (ESI+): calcd for C18H10ClF3N3O2 [M+H]+
392.0414, found 392.0374.
5.15. 10-(4-Chlorophenyl)-9-(triﬂuoromethyl)-2H,3H,4H, 10H-
pyrimido[4,5-b]quinoline-2,4-dione (14)
Prepared using general method 5.7 from 3a (R5,6 = H, R7 = Cl;
61 mg, 0.26 mmol)25 and 4 (R1–3 = H, R4 = CF3, X = F; 60 mg,
0.31 mmol). Yellow solid (28.3 mg, 28%). Mp 372–375 C; IR
(KBr): 3.483 (NH), 1.715 (C@O), 1.659 (C@O), 1.618 (C@C) cm1;
1H NMR: d 7.39 (2H, d, J = 8.6 Hz, Ph 2-H), 7.56 (2H, d, J = 8.6 Hz,
Ph 3-H), 7.67 (1H, t, J = 7.7 Hz, C7-H), 8.20 (1H, dd, 4J = 1.3 Hz,
3J = 7.7 Hz, C8-H), 8.49 (1H, dd, 4J = 1.3 Hz, 3J = 7.7 Hz, C6-H), 9.11
(1H, s, C5-H),11.25 (1H, s, N3-H); 13C NMR: d 116.76 (Cq), 118.70
(Cq), 124.38 (Cq), 124.98 (CH), 128.57 (CH), 133.16 (CH), 134.23
(Cq), 135.60 (CH), 137.03 (CH), 139.24 (Cq), 140.15 (Cq), 143.47
(CH), 156.69 (Cq), 161.14 (Cq), 161.97 (Cq); anal. RP-HPLC: tR
4.37 min (100%, A), 7.17 min (98.2%, B); HRMS (ESI+): calcd for C18-
H10ClF3N3O2 [M+H]+ 392.0414, found 392.0416.
5.16. 10-(3-Chlorophenyl)-9-(triﬂuoromethyl)-2H,3H,4H, 10H-
pyrimido[4,5-b]quinoline-2,4-dione (15)
Prepared using general method 5.7 from 3a (R5,7 = H, R6 = Cl;
60 mg, 0.25 mmol)8 and 4 (R1–3 = H, R4 = CF3, X = F; 58 mg,
0.3 mmol). Yellow solid (54.6 mg, 55%). Mp: 342–343 C (dec); IR
(KBr): 3.421 (NH), 1.706 (C@O), 1.672 (C@O), 1.623 (C@C) cm1;
1H NMR: d 7.37 (1H, d, J = 7.7 Hz, Ph-H), 7.48–7.62 (3H, m, Ph-H),
7.68 (1H, t, J = 7.5 Hz, C7-H), 8.21 (1H, d, J = 7.5 Hz, C8-H), 8.49
(1H, d, J = 7.5 Hz, C6-H), 9.11 (1H, s, C5-H), 11.28 (1H, s, N3-H);
13C NMR: d 116.76 (Cq), 124.45 (Cq), 125.03 (CH), 129.72 (CH),
130.04 (CH), 130.44 (CH), 131.19 (CH), 132.58 (Cq), 135.61 (CH),
135.66 (Cq), 137.06 (CH), 140.04 (Cq), 141.39 (Cq), 143.56 (CH),
156.70 (Cq), 161.16 (Cq), 161.95 (Cq); anal. RP-HPLC: tR 3.54 min
(97.8%, A), 8.69 min (98.9%, B); HRMS (ESI+): calcd for C18H10ClF3-
N3O2 [M+H]+ 392.0408, found 392.0404.
5.17. 10-(3,4-Dichlorophenyl)-9-(triﬂuoromethyl)-2H,3H,4H,
10H-pyrimido[4,5-b]quinoline-2,4-dione (16)
Prepared using general method 5.7 from 3a (R5 = H, R6,7 = Cl;
64 mg, 0.24 mmol)47 and 4 (R1–3 = H, R4 = CF3, X = F; 55 mg,
0.29 mmol). Yellow solid (62.3 mg, 62%). Mp 320–322 C; IR(KBr): 3.486 (NH), 1.705 (C@O), 1.655 (C@O), 1.609 (C@C) cm1;
1H NMR: d 7.46 (1H, dd, 4J = 1.1 Hz, 3J = 8.6 Hz, Ph 6-H), 7.69 (1H,
t, J = 7.8 Hz, C7-H), 7.73 (1H, d, 4J = 1.1 Hz, Ph 2-H), 7.81 (1H, d,
J = 8.6 Hz, Ph 5-H), 8.23 (1H, dd, 4J = 1.6 Hz, 3J = 7.8 Hz, C8-H),
8.50 (1H, dd, 4J = 1.6 Hz, 3J = 7.8 Hz, C6-H), 9.12 (1H, s,C5-H),
11.30 (1H, s, N3-H); 13C NMR: d 116.71 (Cq), 118.33 (Cq), 121.67
(Cq), 124.46 (Cq), 125.13 (CH), 130.37 (CH), 130.94 (Cq), 132.28
(CH), 132.58 (Cq), 133.14 (CH), 135.71 (CH), 137.30 (CH), 139.84
(Cq), 143.71 (CH), 156.61 (Cq), 161.14 (Cq), 161.88 (Cq); anal. RP-
HPLC: tR 6.40 min (99.4%, A), 6.35 min (98.7%, B) HRMS (ESI+): calcd
for C18H9Cl2F3N3O2 [M+H]+ 426.0024, found 426.0034.
5.18. 10-(4-Fluorophenyl)-9-(triﬂuoromethyl)-2H,3H,4H, 10H-
pyrimido[4,5-b]quinoline-2,4-dione (18)
Prepared using general method 5.7 from 3a (R5,6 = H, R7 = F;
58 mg, 0.26 mmol)8 and 4 (R1–3 = H, R4 = CF3, X = F; 60 mg,
0.31 mmol). Yellow solid (45.5 mg, 46%). Mp: >350 C (lit.8 327–
329 C); IR (KBr): 3.420 (NH), 1.716 (C@O), 1.660 (C@O), 1.620
(C@C) cm1; 1H NMR: d 7.29–7.36 (2H, m, Ph 2-H), 7.38–7.45
(2H, m, Ph 3-H), 7.67 (1H, t, J = 7.4 Hz, C7-H), 8.20 (1H, d,
J = 7.4 Hz, C8-H), 8.49 (1H, d, J = 7.4 Hz, C6-H), 9.11 (1H, s, C5-H),
11.24 (1H, s, N3-H); 13C NMR: d 115.41 (CH, d, J = 23.0 Hz),
116.76 (Cq), 118.60 (Cq), 118.91 (Cq), 124.34 (Cq), 124.88 (CH),
133.52 (CH, d, J = 9.3 Hz), 135.57 (CH), 136.97 (CH), 140.44 (Cq),
143.42 (CH), 156.75 (Cq), 162.00 (Cq), 161.31 (Cq), 162.27 (Cq, d,
J = 247.93 Hz); anal. RP-HPLC: tR 2.25 min (100%, A), 27.65 min
(100%, B); HRMS (ESI+): calcd for C18H10F4N3O2 [M+H]+ 376.0709,
found 376.0719.
5.19. 10-(3-Methylphenyl)-9-(triﬂuoromethyl)-2H,3H,4H, 10H-
pyrimido[4,5-b]quinoline-2,4-dione (19)
Prepared using general method 5.7 from 3a (R5,7 = H, R6 = Me;
58 mg, 0.27 mmol)43 and 4 (R1–3 = H, R4 = CF3, X = F; 62 mg,
0.32 mmol). Yellow solid (38.6 mg, 39%). Mp 296–298 C (dec); IR
(KBr): 3.474 (NH), 1.716 (C@O), 1.657 (C@O), 1.619 (C@C) cm1;
1H NMR: d 2.31 (3H, s, Me), 7.08 (1H, s, Ph 2-H), 7.18 (1H, d,
J = 7.6 Hz, Ph 4-H), 7.29 (1H, d, J = 7.6 Hz, Ph 3-H), 7.36 (1H, t,
J = 7.6 Hz, Ph 5-H), 7.66 (1H, t, J = 7.6 Hz, C7-H), 8.18 (1H, dd,
4J = 1.5 Hz, 3J = 7.6 Hz, C8-H), 8.47 (1H, dd, 4J = 1.5 Hz, 3J = 7.6 Hz,
C6-H), 9.10 (1H, s, C5-H), 11.22 (1H, s, N3-H); 13C NMR: d 21.78
(CH3), 116.71 (Cq), 118.95 (Cq), 119.27 (Cq), 124.28 (Cq), 124.82
(CH), 128.12 (CH), 128.66 (CH), 130.10 (CH), 131.11 (CH), 135.51
(CH), 136.79 (CH), 137.96 (Cq), 140.49 (Cq), 143.29 (CH), 156.85
(Cq), 161.23 (Cq), 162.05 (Cq); anal. RP-HPLC: tR 3.00 min (100%,
A), 4.64 min (99.7%, B); HRMS (ESI+): calcd for C19H13F3N3O2
[M+H]+ 372.0960, found 372.0954.
5.20. 10-(4-Methylphenyl)-9-(triﬂuoromethyl)-2H,3H,4H, 10H-
pyrimido[4,5-b]quinoline-2,4-dione (20)
Prepared using method 5.7 from 3a (R5,6 = H, R7 = Me; 59 mg,
0.27 mmol)8 and 4 (R1–3 = H, R4 = CF3, X = F; 62 mg, 0.32 mmol).
Yellow solid (52.1 mg, 52%). Mp 344–346 C (dec); IR (KBr):
3.438 (NH), 1.706 (C@O), 1.681 (C@O), 1.622 (C@C) cm1; 1H
NMR: d 2.38 (3H, s, Me), 7.19 (2H, d, J = 8.4 Hz, Ph 3-H), 7.27 (2H,
d, J = 8.4 Hz, Ph 2-H), 7.65 (1H, t, J = 7.9 Hz, C7-H), 8.17 (1H, dd,
4J = 1.3 Hz, 3J = 7.9 Hz, C8-H), 8.47 (1H, dd, 4J = 1.3 Hz, 3J = 7.9 Hz,
C6-H), 9.09 (1H, s, C5-H), 11.21 (1H, s, N3-H); 13C NMR: d 21.27
(CH3), 116.72 (Cq), 118.94 (Cq), 124.30 (Cq), 124.80 (CH), 128.94
(CH), 130.92 (CH), 135.52 (CH), 136.79 (CH), 138.18 (Cq), 139.12
(Cq), 140.56 (Cq), 143.28 (CH), 156.80 (Cq), 161.29 (Cq), 162.07
(Cq); anal. RP-HPLC: tR 3.13 min (100%, A), 8.57 min (99.7%, B);
HRMS (ESI+): calcd for C19H13F3N3O2 [M+H]+ 372.0960, found
372.0957.
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[4,5-b]quinoline-2,4-dione (21)
Prepared using method 5.7 from 3b (R9 = Bn; 56 mg,
0.26 mmol)48 and 4 (R1–3 = H, R4 = CF3, X = F; 60 mg, 0.31 mmol).
Yellow solid (11.5 mg, 12%). Mp 235–237 C; IR (KBr): 3.416
(NH), 1.706 (C@O), 1.664 (C@O), 1.615 (C@C) cm1; 1H NMR: d
5.87 (2H, s, CH2), 6.81 (2H, d, J = 6.7 Hz, Ph 2-H), 7.13–7.21 (3H,
m, Ph-H), 7.68 (1H, t, J = 7.8 Hz, C7-H), 8.31 (1H, dd, 4J = 1.3 Hz,
3J = 7.8 Hz, C8-H), 8.47 (1H, d, J = 7.8 Hz, C6-H), 9.02 (1H, s, C5-
H), 11.26 (1H, s, N3-H); 13C NMR: d 54.41 (CH2), 117.14 (Cq),
118.17 (Cq), 124.54 (Cq), 125.08 (CH), 126.70 (CH), 127.62 (CH),
128.86 (CH), 135.99 (CH), 136.69 (Cq), 137.34 (CH), 139.88 (Cq),
142.47 (CH), 156.73 (Cq), 160.83 (Cq), 162.02 (Cq); anal. RP-HPLC:
tR 2.34 min (97.5%, A), 8.22 min (96.8%, B); HRMS (ESI+): calcd for
C19H13F3N3O2 [M+H]+ 372.0960, found 372.0973.
5.22. 9-Chloro-10-phenyl-2H,3H,4H,10H-pyrimido[4,5-
b]quinoline-2,4-dione (22)
Prepared using method 5.7 from 3a (R5–7 = H; 62 mg,
0.31 mmol)46 and 4 (R1–3 = H, R4 = CF3, X = F; 59 mg, 0.37 mmol).
Yellow solid (38.8 mg, 39%). Mp > 350 C. IR (KBr): 3.441 (NH),
1.717 (C@O), 1.659 (C@O), 1.615 (C@C) cm1; 1H NMR: d 7.37
(2H, m, Ph 2-H), 7.45–7.54 (3H, m, Ph-H), 7.48 (1H, t, J = 7.8 Hz,
C7-H), 7.83 (1H, dd, 4J = 1.5 Hz, 3J = 7.8 Hz, C8-H), 8.23 (1H, dd,
4J = 1.5 Hz, 3J = 7.8 Hz, C6-H), 9.10 (1H, s, C5-H), 11.18 (1H, s, N3-
H); 13C NMR: d 116.42 (Cq), 121.22 (Cq), 124.57 (Cq), 125.70
(CH), 129.10 (CH), 129.45 (CH), 130.33 (CH), 132.34 (CH), 137.67
(Cq), 139.26 (CH), 139.62 (Cq), 143.26 (CH), 156.75 (Cq), 160.75
(Cq), 162.08 (Cq); anal. RP-HPLC: tR 1.53 min (97.2%, A), 4.59 min
(100%, B); HRMS (ESI+): calcd for C17H11ClN3O2 [M+H]+ 324.0540,
found 324.0513.
5.23. 7-Chloro-10-(2-ﬂuorophenyl)-2H,3H,4H,10H-pyrimido-
[4,5-b]quinoline-2,4-dione (23)
Prepared using method 5.7 from 3a (R5 = F, R6,7 = H; 65 mg,
0.29 mmol)8 and 4 (R1–3 = H, R2 = Cl, X = Cl; 55 mg, 0.35 mmol).
Yellow solid (79.1 mg, 79%). Mp 329–330 C; IR (KBr): 3.427
(NH), 1.707 (C@O), 1.652 (C@O), 1.615 (C@C) cm1; 1H NMR: d
6.84 (1H, d, J = 9.1 Hz, C9-H), 7.51–7.66 (3H, m, Ph-H), 7.71–7.77
(1H, m, Ph-H), 7.80 (1H, dd, 3J = 2.5 Hz, 4J = 9.1 Hz, C8-H), 8.41
(1H, d, 4J = 2.5 Hz, C6-H), 9.12 (1H, s, C5-H), 11.26 (1H, s, N3-H);
13C NMR: d 117.05 (CH), 117.75 (CH, d, J = 19.1 Hz), 118.85 (CH),
122.46 (Cq), 124.72 (Cq, d, J = 13.6 Hz), 126.68 (CH), 129.30 (Cq),
130.67 (CH), 130.93 (CH), 132.75 (CH, d, J = 7.5 Hz), 135.54 (CH),
140.08 (Cq), 142.25 (CH), 157.72 (Cq), 157.57 (Cq, d,
J = 251.6 Hz), 158.79 (Cq), 161.92 (Cq); anal. RP-HPLC: tR
2.05 min (100%, A), 5.34 min (98.6%, B); HRMS (ESI+): calcd for C17-
H10ClFN3O2 [M+H]+ 342.0446, found 342.0399.
5.24. 6-Chloro-10-(4-chlorophenyl)-2H,3H,4H,10H-pyrimido-
[4,5-b]quinoline-2,4-dione (24)
Prepared using general method 5.7 from 3a (R5,6 = H, R7 = Cl;
66 mg, 0.28 mmol)25 and 4 (R1 = Cl, R2–4 = H, X = F; 53 mg,
0.34 mmol). Yellow solid, (37.6 mg, 38%). Mp: 331–332 C (lit.8
220–222 C, dec); IR (KBr): 3.422 (NH), 1.703 (C@O), 1.672
(C@O), 1.607 (C@C) cm1; 1H NMR: d 6.77 (1H, dd, 4J = 2.3 Hz,
3J = 7.1 Hz, C9-H), 7.48 (2H, d, J = 8.7 Hz, Ph 2-H), 7.68–7.71 (2H,
m, C7-H & C8-H), 7.78 (2H, d, J = 8.7 Hz, Ph 3-H), 9.01 (1H, s, C5-
H), 11.27 (1H, s, N3-H); 13C NMR: d 117.22 (Cq), 117.30 (CH),
118.97 (Cq), 125.42 (CH), 130.86 (CH), 130.90 (CH), 134.25 (Cq),
134.72 (Cq), 135.78 (CH), 136.85 (Cq), 137.08 (CH), 143.50 (Cq),
156.69 (Cq), 159.08 (Cq), 162.04 (Cq); anal. RP-HPLC: tR 2.50 min(99.6%; A), 6.05 min (100%, B); HRMS (ESI+): calcd for C17H10Cl2N3-
O2 [M+H]+ 358.0150, found 358.0155.
5.25. 9-Chloro-10-(4-chlorophenyl)-2H,3H,4H,10H-pyrimido-
[4,5-b]quinoline-2,4-dione (25)
Prepared using general method 5.7 from 3a (R5,6 = H, R7 = Cl;
65 mg, 0.27 mmol)25 and 4 (R1–3 = H, R4 = Cl, X = F; 51 mg,
0.32 mmol). Yellow solid (14.6 mg, 15%). Mp > 350 C; IR (KBr):
3.415 (NH), 1.715 (C@O), 1.655 (C@O), 1.613 (C@C) cm1; 1H
NMR: d 7.43–7.52 (3H, m, C7-H & Ph 2-H), 7.60 (2H, d, J = 8.8 Hz,
Ph 3-H), 7.85 (1H, dd, 4J = 1.5 Hz, 3J = 7.9 Hz, C8-H), 8.28 (1H, dd,
4J = 1.5 Hz, 3J = 7.9 Hz, C6-H), 9.09 (1H, s, C5-H), 11.22 (1H, s, N3-
H); 13C NMR: d 116.48 (Cq), 121.00 (Cq), 124.59 (Cq), 125.77
(CH), 129.18 (CH), 132.22 (CH), 132.45 (CH), 134.12 (Cq), 137.53
(Cq), 138.57 (Cq), 139.25 (CH), 143.33 (CH), 156.63 (Cq), 160.81
(Cq), 162.04 (Cq); anal. RP-HPLC: tR 3.10 min (100%; A), 6.34 min
(97.2%; B); HRMS (ESI+): calcd for C17H10Cl2N3O2 [M+H]+
358.0150, found 358.0156.5.26. 9-Chloro-10-(3-chlorophenyl)-2H,3H,4H,10H-pyrimido-
[4,5-b]quinoline-2,4-dione (26)
Prepared using general method 5.7 from 3a (R5,7 = H, R6 = Cl,
65 mg, 0.27 mmol)8 and 4 (R1–3 = H, R4 = Cl, X = F; 51 mg,
0.32 mmol). Yellow solid (29.3 mg, 30%). Mp > 350 C; IR (KBr):
3.416 (NH), 1.715 (C@O), 1.655 (C@O), 1.613 (C@C) cm1; 1H
NMR: d 7.41–7.45 (1H, m, Ph-H), 7.49 (1H, t, J = 7.6 Hz, Ph 5-H),
7.56 (1H, t, J = 8.1 Hz, C7-H), 7.60–7.64 (2H, m, Ph-H), 7.86 (1H,
dd, 4J = 1.2 Hz, 3J = 8.1 Hz, C8-H), 8.25 (1H, dd, 4J = 1.2 Hz,
3J = 8.1 Hz, C6-H), 9.10 (1H, s, C5-H), 11.21 (1H, s, N3-H); 13C
NMR: d 116.39 (Cq), 120.84 (Cq), 124.56 (Cq), 125.82 (CH),
129.40 (CH), 129.60 (CH), 130.35 (CH), 130.62 (CH), 132.46 (CH),
133.31 (Cq), 137.39 (Cq), 139.32 (CH), 140.86 (Cq), 143.46 (CH),
156.62 (Cq), 160.75 (Cq), 161.96 (Cq); anal. RP-HPLC: tR 2.48 min
(100%; A), 8.60 min (98.3%; B); HRMS (ESI+): calcd for C17H10Cl2N3-
O2 [M+H]+ 358.0150, found 358.0151.5.27. 9-Chloro-10-(3-ﬂuorophenyl)-2H,3H,4H,10H-pyrimido-
[4,5-b]quinoline-2,4-dione (27)
Prepared using general method 5.7 from 3a (R5,7 = H, R6 = F;
65 mg, 0.29 mmol)8 and 4 (R1–3 = H, R4 = Cl, X = F; 55 mg,
0.35 mmol). Yellow solid (71.0 mg, 71%). Mp > 365 C; IR (KBr):
3.417 (NH), 1.717 (C@O), 1.658 (C@O), 1.614 (C@C) cm1; 1H
NMR: d 7.28 (1H, d, J = 7.8 Hz, Ph 6-H), 7.38–7.45 (2H, m, Ph-H),
7.49 (1H, t, J = 7.8 Hz, C7-H), 7.53–7.60 (1H, m, Ph-H), 7.86 (1H,
dd, 4J = 1.3 Hz, 3J = 7.8 Hz, C8-H), 8.25 (1H, dd, 4J = 1.3 Hz,
3J = 7.8 Hz, C6-H), 9.10 (1H, s, C5-H), 11.21 (1H, s, N3-H); 13C
NMR: d 116.38 (Cq), 116.59 (CH, d, J = 21.2 Hz), 118.11 (CH, d,
J = 23.8 Hz), 120.94 (Cq), 124.55 (Cq), 125.82 (CH), 126.86 (CH, d,
J = 2.9 Hz), 130.58 (CH, d, J = 8.8 Hz), 132.45 (CH), 137.43 (Cq),
139.33 (CH), 140.88 (Cq, d, J = 10.9 Hz), 143.42 (CH), 156.64 (Cq),
160.73 (Cq), 161.96 (Cq), 162.35 (Cq, d, J = 243.7 Hz); anal. RP-
HPLC: tR 1.63 min (97.0%; A), 19.62 min (98.1%; B); HRMS (ESI+):
calcd for C17H10ClFN3O2 [M+H]+ 342.0446, found 342.0453.5.28. 10-(4-Chlorophenyl)-8-methyl-2H,3H,4H,10H-pyrimido
[4,5-b]quinoline-2,4-dione (28)
Prepared using general method 5.7 from 3a (R5,6 = H, R7 = Cl;
71 mg, 0.3 mmol)25 and 4 (R1,2,4 = H, R3 = Me, X = OTs; 105 mg,
0.36 mmol). Yellow solid (24.3 mg, 24%). Mp 346–347 C (dec); IR
(KBr): 3.441 (NH), 1.694 (C@O), 1.663 (C@O), 1.602 (C@C) cm1;
6876 M. P. Dickens et al. / Bioorg. Med. Chem. 21 (2013) 6868–68771H NMR: d 2.36 (3H, s, Me), 6.57 (1H, s, C9-H), 7.36 (1H, d,
J = 8.1 Hz, C7-H), 7.47 (2H, d, J = 8.5 Hz, Ph 2-H), 7.76 (2H, d,
J = 8.5 Hz, Ph 3-H), 8.12 (1H, d, J = 8.1 Hz, C6-H), 9.08 (1H, s, C5-
H), 11.04 (1H, s, N3-H); 13C NMR: d 22.58 (CH3), 115.06 (Cq),
117.06 (CH), 119.64 (Cq), 126.66 (CH), 130.84 (CH), 130.99 (CH),
131.79 (CH), 134.46 (Cq), 136.95 (Cq), 142.29 (CH), 142.81 (Cq),
147.11 (Cq), 156.80 (Cq), 159.33 (Cq), 162.47 (Cq); anal. RP-HPLC:
tR 2.07 min (98.9%; A), 8.40 min (99.8%; B); HRMS (ESI+): calcd for
C18H13ClN3O2 [M+H]+ 338.0696, found 338.0718.5.29. 9-Bromo-10-phenyl-2H,3H,4H,10H-pyrimido[4,5b]-qui-
noline-2,4-dione (29)
Prepared using general method 5.7 from 3a (R5–7 = H; 56 mg,
0.27 mmol) and 4 (R1–3 = H, R4 = Br, X = OTs; 115 mg, 0.32 mmol).
Yellow solid (29.3 mg, 29%). Mp > 350 C; IR (KBr): 3.413 (NH),
1.717 (C@O), 1.658 (C@O), 1.614 (C@C) cm1; 1H NMR: d 7.37–
7.42 (3H, m), 7.51–7.55 (3H, m), 8.06 (1H, dd, 4J = 1.5 Hz,
3J = 7.8 Hz, C8-H), 8.27 (1H, dd, 4J = 1.5 Hz, 3J = 7.8 Hz, C6-H), 9.06
(1H, s, C5-H), 11.16 (1H, s, N3-H); 13C NMR: d 109.28 (Cq),
116.31 (Cq), 124.76 (Cq), 126.06 (CH), 129.11 (CH), 129.63 (CH),
131.02 (Cq), 131.15 (CH), 132.87 (CH), 138.75 (CH), 138.88 (Cq),
143.19 (CH), 156.73 (Cq), 160.73 (Cq), 162.06 (Cq); anal. RP-HPLC:
tR 1.55 min (98.5%; A), 21.07 min (99.2%; B); HRMS (ESI+): calcd for
C17H11BrN3O2 [M+H]+ 368.0035, found 367.9998.5.30. 9-Bromo-10-(4-chlorophenyl)-2H,3H,4H,10H-pyrimido-
[4,5-b]quinoline-2,4-dione (30)
Prepared using general method 5.7 from 3a (R5,6 = H, R7 = Cl,
60 mg, 0.25 mmol)25 and 4 (R1–3 = H, R4 = Br, X = OTs; 107 mg,
0.3 mmol). Yellow solid (36.4 mg, 36%). Mp > 350 C; IR (KBr):
3.439 (NH), 1.714 (C@O), 1.655 (C@O), 1.610 (C@C) cm1; 1H
NMR: d 7.40 (1H, t, J = 7.7 Hz, C7-H), 7.44 (2H, d, J = 8.7 Hz, Ph 2-
H), 7.61 (2H, d, J = 8.7 Hz, Ph 3-H), 8.08 (1H, dd, 4J = 1.5 Hz,
3J = 7.7 Hz, C8-H), 8.27 (1H, dd, 4J = 1.5 Hz, 3J = 7.7 Hz, C6-H), 9.06
(1H, s, C5-H), 11.19 (1H, s, N3-H); 13C NMR: d 109.12 (Cq),
116.30 (Cq), 124.76 (Cq), 126.15 (CH), 129.18 (CH), 132.95 (CH),
132.96 (CH), 134.33 (Cq), 137.72 (Cq), 138.72 (Cq), 143.19 (CH),
143.34 (CH), 156.68 (Cq), 160.84 (Cq), 162.04 (Cq); anal. RP-HPLC:
tR 2.73 min (97.6%; A), 4.17 min (100%; B); HRMS (ESI+): calcd for
C17H10BrClN3O2 [M+H]+ 401.9645, found 401.9613.5.31. Molecular modeling
Flexible docking was carried out using OMEGA, version 2.1.6,
OEDocking, version 3.0.0, and VIDA, version 4.1.2, OpenEye Scien-
tiﬁc Software, Inc., Santa Fe, NM, USA, www.eyesopen.com, 2012.
Chain A (E3 ubiquitin-protein ligase domain of MDM2, residues
428–491) from PDB entry 2VJF was extracted and a docking recep-
tor was constructed using the OEDocking application Make Recep-
tor. The structure of the entire chain was set as the ligand box
(23.0 Å  29.7 Å  25.7 Å; 17,513 Å2) and molecular cavity detec-
tion was used with default settings. The balanced binding site
shape potential resulting from this included all protein surface cav-
ities (total contour 2315 Å2), with an inner contour (53 Å2) encom-
passing the binding site of the C-terminus of HDMX (chain B
488FIA490) observed in 2VJF. Multiconformer databases of the bioac-
tive compounds (Table 1) were created (OMEGA; default settings),
and these were docked to the above receptor with default settings
and no constraints. For each compound up to 10 binding poses
were ranked using the Chemgauss 4 scoring function. The majority
(>80%) of docking poses with scores <-3 kcal/mol placed the ligand
at the C-terminal tripeptide HDMX binding site observed in 2VJF.Acknowledgments
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